RetroSense Therapeutics Doses First Patient in Phase I/II Clinical Trial for Lead Compound RST-001
ANN ARBOR, Mich.--(BUSINESS WIRE)--RetroSense Therapeutics LLC, a privately-held biopharmaceutical company, today announced that the first patient has been successfully dosed in the first clinical trial to evaluate the safety of RST-001. The study is titled Phase I/IIa, Open-Label, Dose-Escalation Study of Safety and Tolerability of Uniocular Intravitreal RST-001 in Patients With Retinitis Pigmentosa (RP). RST-001 is designed to restore some vision in RP, a genetic condition that leads to the p
